Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study

Cardiology
Ole FaergemanECLIPSE Study Investigators

Abstract

Patients at high risk of cardiovascular disease frequently fail to reach recommended low-density lipoprotein cholesterol (LDL-C) goals, partly because statin doses are not titrated to optimal effect. The ECLIPSE study was designed to compare the efficacy and safety of force-titrated treatment with rosuvastatin (10-40 mg) with that of atorvastatin (10-80 mg) in high-risk patients with hypercholesterolemia. In this 24-week, open-label, randomized, multinational, parallel-group study, 1,036 patients were randomized to rosuvastatin (n = 522) or atorvastatin (n = 514). At all time points, a significantly greater percentage of patients on rosuvastatin treatment achieved the NCEP ATP III LDL-C goal of <100 mg/dl (2.5 mmol/l), the 2003 European LDL-C target of <2.5 or 3.0 mmol/l (100 or 115 mg/dl) and the LDL-C goal of <70 mg/dl (1.8 mmol/l), a goal suggested for very high-risk patients (p < 0.001 for all). Rosuvastatin also achieved significantly greater improvements in components of the atherogenic lipid profile versus atorvastatin. Both treatments were well tolerated. Rosuvastatin titrated across its recommended dose range provides a more favorable effect on lipoprotein variables than atorvastatin, enabling more high-risk patients t...Continue Reading

Citations

Sep 24, 2008·Archives of Cardiovascular Diseases·Stephane Hatem, Franck Boccara
Nov 11, 2009·Expert Review of Cardiovascular Therapy·Vivencio Barrios, Carlos Escobar
Oct 18, 2011·Expert Opinion on Drug Safety·Peter P Toth, Thomas D Dayspring
May 29, 2012·International Journal of Cardiology·Gianluigi SavaresePasquale Perrone-Filardi
May 7, 2013·European Journal of Preventive Cardiology·Mike K PalmerBjörn W Karlson
Nov 22, 2014·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Mar 12, 2015·The Cochrane Database of Systematic Reviews·Stephen P AdamsJames M Wright
Mar 24, 2012·Clinical Medicine Insights. Cardiology·Ahai LuvaiJulian H Barth
Apr 2, 2014·Postgraduate Medicine·Peter P Toth
Jun 10, 2021·Expert Review of Cardiovascular Therapy·Chrysoula BoutariVasilios G Athyros
Nov 26, 2009·Current Opinion in Lipidology

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.